Genenta Science (ADR)
Develops tumor-targeted gene therapy and staged Italian defense and aerospace investments.
Something off on this page? Send us feedback.
Profile
Develops Temferon, an investigational tumor-targeted gene therapy, while pursuing staged control investments in Italian defense and aerospace businesses. The model combines externally supported clinical development with a planned portfolio of regulated industrial operators.
Develops Temferon, an autologous stem/progenitor-cell gene therapy designed to direct interferon-alpha into solid-tumor microenvironments through its myeloid-cell progeny. The investigational program completed a glioblastoma study and continues clinical work in genitourinary tumors, using research and clinical relationships in Milan while collaboration options remain under review.
Is moving from a clinical-stage biotechnology focus toward staged investments in Italian national-security-regulated businesses. A.T.C. makes high-precision tactical rifles and weapon systems; Sòphia High Tech provides aerospace-and-defense engineering and manufacturing. Both investments are structured to progress from minority ownership to control under operating, licensing, contractual and regulatory conditions. Temferon has no approved product, sales or distribution infrastructure, and the corporate-purpose expansion remains suspended.
Company facts
Key statistics
Year to date −28.4% · Average volume (30d) 54.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026Q4 FY25 | −$0.36 | −$0.36 | 0.0% | — | — | — | +3.75% |
| Feb 25, 2026Q4 FY25 | −$0.36 | −$0.36 | 0.0% | — | — | — | −3.99% |
| Jun 30, 2024 | — | −$0.24 | — | — | — | — | −0.65% |
| Apr 24, 2024 | −$0.42 | −$0.30 | +29.7% | — | $5.5M | — | +14.12% |
Financial highlights
| 12 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$24.3K | −$24.3K | −$25.8K | −$27.1K | −$15.1K | −$16.3K | |
| Operating income | −$7.8M | −$5.6M | −$5.3M | −$6.4M | −$3.7M | −$3.7M | |
| Net income | −$7.8M | −$5.6M | −$4.7M | −$5.9M | −$4.1M | −$3.1M | |
| Diluted EPS | −$0.43 | −$0.31 | −$0.25 | −$0.31 | −$0.23 | −$0.15 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Balance sheet, Dec 31, 2025Cash & short-term investments $32.6M · Total debt $8.8M · Total assets $36.9M · Shareholders' equity $25.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 19.15M · Float 13.87M · 72.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Fidim S.p.A. | 5.43M | 23.00% | 13D | May 5, 2026 |
| Paracchi Pierluigi · director, 10 percent owner, officer: Chief Executive Officer | 2.28M | 11.88% | Form 4 | Mar 18, 2026 |
| Eurizon Capital SGR S.P.A. | 360.0K | 1.88% | 13F | May 8, 2026 |
| Allianz SE | 234.1K | 1.22% | 13F | May 11, 2026 |
| Cartesian Growth Corp | 200.3K | 1.05% | 13F | May 7, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Candel Therapeutics
Oncolytic immunotherapy rival in glioblastoma.
- Novocure
Established glioblastoma therapy competing for the same patients.
- Merck
Checkpoint-inhibitor regimens dominate the renal-cell pathway.
- Bristol-Myers Squibb
Opdivo-based combinations are leading RCC treatment options.
- ImmunityBio
Cytokine and NK-cell immunotherapy challenger across solid tumors.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genenta Science (ADR) | $1.00 | −0.99% | $19.1M | — | — | — | — |
| Candel Therapeutics | $13.07 | +0.08% | $957.6M | — | — | — | — |
| Novocure | $17.66 | −0.95% | $2.08B | — | — | 3.0 | +15.6% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| ImmunityBio | $8.07 | +0.25% | $8.43B | — | — | 50.9 | +93.9% |
| Median | 66.7 | 13.8 | 4.2 | +10.7% |